|
|
|
| Meta-analysis of the efficacy of Chaishao Liujunzi Decoction combined with transarterial chemoembolization in the treatment of primary liver cancer |
| QIU Han-bo1 ZHAO Yi-man1 ZHOU Yao-hong1 ZHENG Jing-hui2 PENG Qi-long2 HOU En-cun |
1.Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530011, China;
2.Department of Cardiology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530011, China |
|
|
|
|
Abstract Objective To systematically evaluate the efficacy of Chaishao Liujunzi Decoction combined with transarterial chemoembolization (TACE) in the treatment of primary liver cancer.Methods The Chinese and English literature databases were searched by computer, and randomized controlled studies (RCTs) of Chaishao Liujunzi Decoction combined with TACE (experimental group) and TACE (control group) on patients with advanced primary liver cancer were searched.The retrieval time was from the time of building the repository to November 30, 2019.RevMan 5.3 software was used for Meta-analysis.Results The Meta-analysis showed that the Karnofsky performance status (KPS) score of the experimental group was higher than that of the control group (MD=9.43, 95%CI=6.59-12.27, P＜0.000 01), the increase of bilirubin was lower than that of the control group(RR=0.48,95%CI=0.31-0.74,P=0.001),the nausea and vomiting was lower than that of the control group(RR=0.54,95%CI=0.31-0.94,P=0.03),the abdominal pain was lower than that of the control group (RR=0.56, 95%CI=0.40-0.79, P=0.001), and the fever was lower than that of the control group (RR=0.60, 95%CI=0.42-0.85, P=0.005), and the differences were statistically significant.There were no significant differences in solid tumor control (RR=1.04, 95%CI=0.93-1.17, P=0.48), leukopenia (RR=0.76, 95%CI=0.48-1.20, P=0.24)and thrombocytopenia (RR=0.81, 95%CI=0.52-1.24, P=0.32) between the two groups.Conclusion Chaishao Liujunzi Decoction combined with TACE can significantly improve KPS score and reduce the occurrence of adverse reactions to chemotherapy.
|
|
|
|
|
|
| [1] |
张爽，王锋，孟庆玲，等.原发性肝癌患者流行病学与乙型肝炎病毒感染调查[J].中国疫苗和免疫，2018，24（2）：133-136，151.
|
| [2] |
Abdel-Rahman O，Elsayed ZA.Combination trans arterial chemoembolization（TACE） plus sorafenib for the management of unresectable hepatocellular carcinoma：a systematic review of the literature[J].Dig Dis Sci，2013，58（12）：3389-3396.
|
| [3] |
黄燊，杨成雷，张志明.肝细胞癌的靶向治疗[J].临床肝胆病杂志，2019，35（11）：2573-2577.
|
| [4] |
胡铭洋，吴绮楠，吴永忠.肝癌的靶向和免疫治疗[J].重庆医科大学学报，2019，44（12）：1547-1552，1524.
|
| [5] |
Bruix J，Sherman M，American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma：an update[J].Hepatology，2011，53（3）：1020-1022.
|
| [6] |
Strobel O，Büchler MW.Treatment effect of liver resectionvs.RFA or TACE in hepatocellular carcinoma[J].Chirurg，2019，90（Suppl 2）：75.
|
| [7] |
Johnson BW，Wright GP.Regional therapies for the treatment of primary and metastatic hepatic tumors：A diseasebased review of techniques and critical appraisal of current evidence[J].Am J Surg，2019，217（3）：541-545.
|
| [8] |
张程，孙建光，解观月.中药汤剂联合TACE 治疗原发性肝癌的Meta 分析[J].湖南中医杂志，2018，34（12）：104-108.
|
| [9] |
郑捷文，张丹，吴嘉瑞，等.基于Meta 分析的复方苦参注射液辅助治疗肝癌临床评价研究[J].药物流行病学杂志，2017，26（11）：745-750.
|
| [10] |
中华人民共和国卫生部医政司.中国常见肿瘤诊治规范第二分册 原发性肝癌[S].2 版.北京：北京医科大学中国协和医科大学联合出版社，1991：16.
|
| [11] |
中华人民共和国卫生部医政司.中国常见恶性肿瘤诊治规范（合订本）[M].北京：北京医科大学中国协和医科大学联合出版社，1995：12-13.
|
| [12] |
中华人民共和国卫生部.原发性肝癌诊疗规范（2011年版）[J].临床肝胆病杂志，2011，20（11）：929-946.
|
| [13] |
中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范（2017年版）[J].临床肝胆病杂志，2017，33（8）：1419-1431.
|
| [14] |
Higgins JP，Altman DG，Gtzsche PC，et al.The Cochrane Collaboration′s tool for assessing risk of bias in randomised trials[J].BMJ，2011，343：d5928.
|
| [15] |
Coory MD.Comment on：Heterogeneity in meta-analysis should be expected and appropriately quantified[J].Int J Epidemiol，2011，39（3）：932.
|
| [16] |
石修权，王增珍.Egger′s test 与Begg′s test 的功效差异比较与原因分析[J].华中科技大学学报（医学版），2009，38（1）：91-93，102.
|
| [17] |
龚辉，唐建清，陈州华，等.柴芍六君子汤防治肝癌TACE术后栓塞综合征的临床研究[J].中医药导报，2018，24（22）：36-38.
|
| [18] |
张洪新.柴芍六君子汤在原发性肝癌介入治疗中的应用[J].黑龙江医药科学，2017，40（5）：59-60.
|
| [19] |
徐森华，徐成兴，瞿春霞，等.加味柴芍六君子汤联合经肝动脉化疗栓塞治疗原发性肝癌临床观察[J].介入放射学杂志，2014，23（2）：163-167.
|
| [20] |
张红，王艳云，张志芳，等.柴芍六君子汤加味防治肝郁脾虚型肝癌介入化疗栓塞术后综合征临床观察[J].湖南中医药大学学报，2007，27（6）：55-57.
|
| [21] |
毛春晖，袁轶峰.柴芍六君子汤防治原发性肝癌介入治疗后副反应的临床观察[J].中医药导报，2007，13（9）：25-26.
|
| [22] |
Woo HY，Heo J.New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis[J].Clin Mol Hepatol，2015，21（2）：115-121.
|
| [23] |
黎经何，史政荣.原发性肝癌术后辅助经导管动脉栓塞术的研究进展[J].中国医药导报，2020，17（3）：34-37.
|
| [24] |
梁宏元，卢再鸣.原发性肝癌综合介入治疗现状与困惑[J].临床肝胆病杂志，2016，32（1）：44-48.
|
| [25] |
冯振兴，强胜.小柴胡汤的药理作用及临床应用简况[J].中国医药科学，2020，10（22）：49-51.
|
| [26] |
居艳娟，李荣平，郭迪斌，等.白芍总苷对类风湿关节炎肝功能保护、佐治效果研究[J].中国现代医生，2019，57（30）：34-37.
|
| [27] |
王智，徐云丹，赵刚.四君子汤与氟尿嘧啶联用对肝癌Bel-7402 细胞生长的抑制作用[J].湖北中医杂志，2010，32（9）：5-6.
|
|
|
|
